ClinicalTrials.gg
CompletedNCT01972217Updated Nov 14, 2023Results posted

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

A Phase 2 interventional study of Olaparib and Placebo in Metastatic Castration-resistant Prostate Cancer, sponsored by AstraZeneca. Completed at 41 sites in 11 countries. Open to male participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-11-14.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing olaparib in Prostatic Neoplasms — 2 open to participants now, 11 under way, 2 of them phase 3. olaparib · Prostatic Neoplasms.

Enrollment
5th of 25
158 · median 43
Started
2014
the only one that year
Phase 2
14 of 25
2 open now
Registered
1st of 25
by date
Lead sponsor
5 of 25
AstraZeneca

Among the 25 studies testing olaparib in Prostatic Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2014, is one of 14 in phase 2, and was the 1st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 25 studies testing olaparib in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 130 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing olaparib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and pharmacokinetics (PK) of olaparib when given in addition to abiraterone 1000 mg once daily. Part B is a randomised, double-blind, placebo controlled comparison of the efficacy, safety and tolerability of the dose of olaparib selected from Part A when given in addition to abiraterone, versus placebo given in addition to abiraterone. Abiraterone is indicated in combination with prednisone or prednisolone for the treatment of patients with metastatic CRPC. Prednisone or prednisolone 5 mg twice daily (bid) will be administered with the abiraterone in this study.

Read the detailed description

This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and PK of olaparib when given in addition to abiraterone 1000 mg once daily. Part B is a randomised, double-blind, placebo-controlled comparison of the efficacy, safety and tolerability of the dose of olaparib selected from Part A when given in addition to abiraterone, versus placebo in addition to abiraterone.

Abiraterone is indicated in combination with prednisone or prednisolone for the treatment of patients with metastatic CRPC. Prednisone or prednisolone 5 mg bid will be administered with the abiraterone in this study, but throughout this protocol the treatment will be referred to simply as abiraterone.

For Part A of the study, 15 to 18 evaluable patients (Cohorts 1 and 2) are planned to be enrolled from approximately 4 sites in approximately 1 or 2 countries, and a further 12 patients may be recruited into a 3rd cohort if necessary.

For Part B of the study, approximately 140 patients who have received prior chemotherapy containing docetaxel will be randomised from approximately 40 sites in North America and Europe. Patients who have been dosed in Part A of the study may not participate in Part B.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • Olaparib
  • castration-resistant, metastatic prostate cancer
  • Prior Docetaxel Chemotherapy
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated written prior to any study specific procedures.
  2. Male aged 18 years and older.
  3. or cytologically proven diagnosis of prostate cancer.
  4. Candidate for abiraterone therapy with documented evidence of castration-resistant prostate cancer. Metastatic status is defined as at least one documented metastatic lesion on either bone scan or CT/MRI scan. Castration resistant prostate cancer is defined as rising PSA or other signs of disease progression despite treatment with androgen deprivation therapy and the presence of a castrate level of testosterone (≤50 ng/dL).
  5. (ECOG) performance status 0 to 2 with no deterioration over the previous 2 weeks.
  6. Patients must have a ≥12 weeks.
  7. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations, and completing PRO instruments.
  8. Patients must be on a stable concomitant medication regimen, defined as no changes in medication or in dose within 2 weeks prior to start of olaparib dosing, except for bisphosphonates, denosumab and , which should be stable for at least 4 weeks prior to start of olaparib dosing.
  9. For the randomised phase only, patients must have received chemotherapy in the form of docetaxel treatment for metastatic castration-resistant prostate cancer. Note: patients who discontinued docetaxel for toxicity reasons and without completing the full course will still be eligible to enter this study provided they received at least 2 cycles of chemotherapy.

Provide informed consent for the pharmacogenetic sampling and analyses.

Exclusion criteria

Exclusion Criteria:

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff, its agents and/or staff at the study site).
  2. Previous treatment in the present study.
  3. Treatment with any of the following:

    • Previous exposure to any 2nd generation anti-hormonal including abiraterone and enzalutamide
    • More than 2 prior courses of chemotherapy for prostate cancer
    • Previous use of immunotherapy or radium-223 for the treatment of metastatic prostate cancer
    • Any agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment;
    • Any previous exposure to a CYP17 (17α-hydroxylase/C17,20-lyase) inhibitor;
    • Substrates of CYP2D6 with a narrow therapeutic index (eg, thioridazine);
    • Potent inhibitors or inducers of within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort).
    • Any previous treatment with a PARP inhibitor, including olaparib.
  4. With the exception of alopecia or toxicities related to the use of gonadotropinreleasing hormone agonists, any unresolved toxicities from prior therapy greater than Grade 2 at the time of starting study treatment.
  5. Spinal cord compression or unless asymptomatic, treated and stable and not requiring for at least 4 weeks prior to start of study treatment.
  6. As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including , and (HIV). Screening for chronic conditions is not required.
  7. Any of the following cardiac criteria:

    • Mean resting >470 msec obtained from 3 ECGs
    • Any abnormalities in rhythm, conduction or morphology of resting eg, complete left bundle branch block, third degree heart block
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval.
  8. Other within the last 5 years except: adequately treated non-melanoma skin cancer or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.
  9. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

    • (ANC) \<1.5 x 109/L
    • count \<100 x 109/L
    • (Hb) \<100 g/L
    • (AST) or alanine aminotransferase (ALT) >2.5 x (ULN) if no demonstrable liver metastases or >5 x ULN in the presence of liver metastases
    • Total >1.5 x ULN if no liver metastases or >3 x ULN in the presence of liver metastases (except in the case of Gilbert's disease)
    • Creatinine >1.5 x ULN concurrent with \<50 mL/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is >1.5 x ULN
    • If bone metastases are present and liver function is otherwise considered adequate by the Investigator then elevated alkaline phosphatase (ALP) will not exclude the patient.
  10. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of olaparib or abiraterone.
  11. History of to active or inactive of olaparib or abiraterone or drugs with a similar chemical structure or class to olaparib or abiraterone.
  12. Patients with myelodysplastic syndrome/acute myeloid leukaemia.
  13. Current disease or condition known to interfere with absorption, distribution, metabolism, or excretion of drugs, at the Investigator's discretion.
  14. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
  15. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

    Exclusion from the genetic research may be for any of the exclusion criteria specified in the main study or any of the following:

  16. Previous bone marrow transplant.
  17. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the pharmacogenetic sample collection.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
158 participants (actual)

Study arms

  • Active comparator
    Olaparib

    200 mg or 300 mg bid

    Drug: Olaparib · Drug: Abiraterone · Drug: Prednisone or prednisolone

  • Placebo comparator
    Placebo

    placebo to match olaparib bid

    Drug: Placebo · Drug: Abiraterone · Drug: Prednisone or prednisolone

Interventions

  • Olaparib bid

    Also known as: PARP inhibition

  • DrugPlacebo

    Placebo bid

    Also known as: Placebo to PARP inhibition

  • Abiraterone 1000 mg

  • DrugPrednisone or prednisolone

    Drug pages: Prednisone · Prednisolone

    Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.

06

What researchers measure

Primary outcomes

  1. Part A: Percentage of Patients Experiencing Adverse Events (AEs)

    The safety and tolerability of olaparib in combination with abiraterone was assessed during Part A of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented. Severity of AEs was assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events (CTCAE) v4.0. AEs were assigned to a Grade from 1 through 5 as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. 'c-r' = causally related 'discont' = discontinuation.

    Time frame: Cohort 1 and 2: From baseline in Part A (Day 1 for each cohort) up to 30 days following last dose of study treatment.

  2. Part A: Number of Patients With Dose Limiting Toxicities (DLTs)

    DLTs were assessed by a Safety Review Committee (SRC) after a minimum of 3 patients had received at least 14 days of treatment in Part A. A DLT was defined as any toxicity which was not a recognised AE of abiraterone or prednisolone, and was not attributable to the disease or disease-related processes under investigation, which occurred during a minimum period of 14 days treatment and which included: 1. haematological toxicity CTCAE v4.0 Grade 4 or higher present for more than 4 days (except anaemia); 2. non-haematological toxicity CTCAE v4.0 Grade 3 or higher including infection, corrected QT interval prolongation; 3. any other toxicity that was greater than that at baseline, was clinically significant and/or unacceptable, did not respond to supportive care, resulted in a disruption of dosing schedule of 7 days or more, or was judged to be a DLT by the SRC. A DLT excluded alopecia and isolated laboratory changes of any grade without clinical sequelae or clinical significance.

    Time frame: From Day 1 for Cohort 1 and from Day 4 for Cohort 2 up to 14 days treatment with olaparib + abiraterone for 3 patients.

  3. Part B: Median Radiological Progression-Free Survival (rPFS) Time

    The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (for soft tissue disease) and Prostate Cancer Working Group 2 (PCWG-2) (for bone disease) criteria, or death. Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion. Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit).

    Time frame: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.

  4. Part B: Percentage of Patients With Progression Events or Death (rPFS)

    The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using RECIST version 1.1 (for soft tissue disease) and PCWG-2 (for bone disease) criteria, or death. Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion. Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit). The percentage of patients with progression events is presented overall and according to RECIST 1.1 and/or PCWG-2 criteria, or death.

    Time frame: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.

Secondary outcomes

  1. Part A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)

    Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

    Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  2. Part A PK: Abiraterone Cmax,ss

    Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

    Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  3. Part A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)

    Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib tmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

    Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  4. Part A PK: Abiraterone Tmax,ss

    Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone tmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

    Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  5. Part A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)

    Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmin,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

    Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  6. Part A PK: Abiraterone Cmin,ss

    Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmin,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

    Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  7. Part A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)

    Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib AUCss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

    Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  8. Part A PK: Abiraterone AUCss

    Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone AUCss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

    Time frame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  9. Part B: Percentage of Patients Experiencing AEs

    The safety and tolerability of olaparib when given in combination with abiraterone was assessed during Part B of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented. Severity of AEs was assessed using the NCI Common Terminology CTCAE v4.0. AEs were assigned to a Grade from 1 through 5 as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. 'c-r' = causally related. 'discont' = discontinuation. 'ola/pla' = olaparib/placebo.

    Time frame: From first dose of study treatment following randomisation in Part B up to 30 days following last dose of study treatment (up to approximately 3 years).

  10. Part B: Median Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Levels

    The best percentage change from baseline in PSA levels was determined to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone. The best percentage change was defined as the biggest reduction in PSA level compared with baseline or smallest increase in the absence of a decrease.

    Time frame: From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.

  11. Part B: Percentage of Patients With PSA Responses

    The percentages of patients with single visit responses and with confirmed responses are presented to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone. A single visit response was defined as any post-dose visit PSA level reduced by 50% or more compared with baseline. A confirmed response was defined as a reduction in PSA level of 50% or more on 2 consecutive occasions at least 4 weeks apart compared with baseline. Patients may have had more than 1 single visit response or confirmed response but were counted once.

    Time frame: From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.

  12. Part B: Median Best Percentage Change From Baseline in Circulating Tumour Cell (CTC) Level

    The median best percentage change from baseline in CTC levels was determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone. The best percentage change was defined as the biggest CTC level reduction compared with baseline or smallest increase in the absence of a decrease.

    Time frame: From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.

  13. Part B: Percentage of Patients With at Least One Objective Response (Objective Response Rate [ORR])

    The overall radiological ORR was calculated to assess the anti-tumour activity of olaparib in combination with abiraterone, compared with placebo in combination with abiraterone. The best overall ORR was defined as the percentage of patients with at least 1 visit response of complete response (CR) or partial response (PR) in soft tissue disease assessed by RECIST 1.1 and also bone scan status of non-progressive disease or non-evaluable for their bone scans assessed by PCWG-2. CR: Disappearance of all target lesions. Reduction of pathological lymph nodes to \<10 millimetres. PR: At least a 30% decrease in the sum of diameters of target lesions from baseline. The percentage of patients with a response is presented.

    Time frame: From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.

  14. Median Time to First Subsequent Therapy (TFST) and Median Time to Second Subsequent Therapy (TSST)

    The TFST and TSST were determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone. TFST was defined as the time from randomisation to the earlier of first subsequent anti-cancer therapy start date following study treatment discontinuation, or death. TSST was defined as the time from randomisation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death.

    Time frame: From randomisation until analysis cut-off date (up to approximately 3 years).

  15. Part B: Median Overall Survival (OS)

    OS was determined to assess the efficacy of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone. OS was performed at the time of the analysis of rPFS, and the median OS, calculated using the Kaplan-Meier technique, is presented.

    Time frame: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.

  16. Part B: Median Time to Second Progression or Death (PFS2)

    The efficacy of olaparib when given in combination with abiraterone was assessed by PFS2, defined by local standard clinical practice and included objective radiological progression by RECIST 1.1 (soft tissue), symptomatic progression, rise in PSA level or death in the absence of overall progression.

    Time frame: From randomisation until analysis cut-off date (up to approximately 3 years).

07

Results

Posted Oct 2, 2018

Participant flow

In this 2-part study, patients with metastatic castrate-resistant prostate cancer (mCRPC) were recruited at 41 sites in Europe, Russia and North America. Part A had 2 cohorts for olaparib dose selection when given with approved treatment abiraterone. Part B compared olaparib versus placebo both with abiraterone in post-chemotherapy mCRPC patients.

Part A: Open-label Safety Run-in Period
Participant flow — Part A: Open-label Safety Run-in Period
MilestonePart A Cohort 1: Olaparib 200 mg + AbirateronePart A Cohort 2: Olaparib 300 mg + AbirateronePart B: Olaparib + AbirateronePart B: Placebo + Abiraterone
Started31300
Completed2100
Not completed11200
Withdrew: Withdrawal by subject0100
Withdrew: Condition under investigation worsened1900
Withdrew: Adverse event0100
Withdrew: Death0100
Part B Double-blind, Randomised Period
Participant flow — Part B Double-blind, Randomised Period
MilestonePart A Cohort 1: Olaparib 200 mg + AbirateronePart A Cohort 2: Olaparib 300 mg + AbirateronePart B: Olaparib + AbirateronePart B: Placebo + Abiraterone
Started007171
Received olaparib/placebo007171
Received abiraterone007171
Completed002524
Not completed004647
Withdrew: Death004344
Withdrew: Reason not recorded0010
Withdrew: Screen failure0001
Withdrew: Lost to follow-up0021
Withdrew: Withdrawal by subject0001

Outcome measures

PrimaryPart A: Percentage of Patients Experiencing Adverse Events (AEs)

The safety and tolerability of olaparib in combination with abiraterone was assessed during Part A of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented. Severity of AEs was assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events (CTCAE) v4.0. AEs were assigned to a Grade from 1 through 5 as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. 'c-r' = causally related 'discont' = discontinuation.

Time frame:
Cohort 1 and 2: From baseline in Part A (Day 1 for each cohort) up to 30 days following last dose of study treatment.
Reported as:
Number · Percentage of patients
Part A: Percentage of Patients Experiencing Adverse Events (AEs)
Percentage of patientsPart A Cohort 1: Olaparib 200 mg + AbirateronePart A Cohort 2: Olaparib 300 mg + Abiraterone
Any AE c-r to olaparib + abiraterone66.746.2
Any AE c-r to olaparib only33.37.7
Any AE c-r to abiraterone only015.4
Any AE CTCAE Grade 3 or higher66.723.1
Any AE CTCAE Grade 3 or higher c-r to olaparib07.7
Any AE CTCAE Grade 3 or higher c-r to abiraterone07.7
Any AE with outcome = death00
Any serious AE (SAE)66.723.1
Any SAE c-r to olaparib00
Any SAE c-r to abiraterone00
Any AE causing discont of olaparib07.7
Any AE causing discont of olaparib c-r to olaparib00
Any AE causing discont olaparib c-r to abiraterone00
PrimaryPart A: Number of Patients With Dose Limiting Toxicities (DLTs)

DLTs were assessed by a Safety Review Committee (SRC) after a minimum of 3 patients had received at least 14 days of treatment in Part A. A DLT was defined as any toxicity which was not a recognised AE of abiraterone or prednisolone, and was not attributable to the disease or disease-related processes under investigation, which occurred during a minimum period of 14 days treatment and which included: 1. haematological toxicity CTCAE v4.0 Grade 4 or higher present for more than 4 days (except anaemia); 2. non-haematological toxicity CTCAE v4.0 Grade 3 or higher including infection, corrected QT interval prolongation; 3. any other toxicity that was greater than that at baseline, was clinically significant and/or unacceptable, did not respond to supportive care, resulted in a disruption of dosing schedule of 7 days or more, or was judged to be a DLT by the SRC. A DLT excluded alopecia and isolated laboratory changes of any grade without clinical sequelae or clinical significance.

Time frame:
From Day 1 for Cohort 1 and from Day 4 for Cohort 2 up to 14 days treatment with olaparib + abiraterone for 3 patients.
Reported as:
Number · Patients
Part A: Number of Patients With Dose Limiting Toxicities (DLTs)
PatientsPart A Cohort 1: Olaparib 200 mg + AbirateronePart A Cohort 2: Olaparib 300 mg + Abiraterone
Part A: Number of Patients With Dose Limiting Toxicities (DLTs)24
PrimaryPart B: Median Radiological Progression-Free Survival (rPFS) Time

The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (for soft tissue disease) and Prostate Cancer Working Group 2 (PCWG-2) (for bone disease) criteria, or death. Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion. Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit).

Time frame:
From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.
Reported as:
Median · Months
Part B: Median Radiological Progression-Free Survival (rPFS) Time
MonthsPart B: Olaparib + AbirateronePart B: Placebo + Abiraterone
Part B: Median Radiological Progression-Free Survival (rPFS) Time13.8 (10.8 to 20.4)8.2 (5.5 to 9.7)
PrimaryPart B: Percentage of Patients With Progression Events or Death (rPFS)

The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using RECIST version 1.1 (for soft tissue disease) and PCWG-2 (for bone disease) criteria, or death. Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion. Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit). The percentage of patients with progression events is presented overall and according to RECIST 1.1 and/or PCWG-2 criteria, or death.

Time frame:
From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.
Reported as:
Number · Percentage of patients
Part B: Percentage of Patients With Progression Events or Death (rPFS)
Percentage of patientsPart B: Olaparib + AbirateronePart B: Placebo + Abiraterone
Part B: Percentage of Patients With Progression Events or Death (rPFS)64.876.1
Statistical analysis
  • Part B: Olaparib + Abiraterone vs Part B: Placebo + Abiraterone · Log Rank · p = 0.017 · Hazard ratio (hr): 0.651 · 95% CI 0.438 to 0.969
SecondaryPart A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)

Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

Time frame:
PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Reported as:
Geometric mean · micrograms per millilitre (mcg/mL)
Part A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)
micrograms per millilitre (mcg/mL)Part A Cohort 2 Group 1: Olaparib, Olaparib + AbirateronePart A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone
Olaparib alone7.781 ± 25.06—
Olaparib + abiraterone6.504 ± 20.907.724 ± 28.05
SecondaryPart A PK: Abiraterone Cmax,ss

Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

Time frame:
PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Reported as:
Geometric mean · nanograms per millilitre (ng/mL)
Part A PK: Abiraterone Cmax,ss
nanograms per millilitre (ng/mL)Part A Cohort 2 Group 1: Olaparib, Olaparib + AbirateronePart A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone
Abiraterone alone—145.8 ± 135.5
Olaparib + abiraterone130.7 ± 68.8786.12 ± 48.88
SecondaryPart A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)

Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib tmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

Time frame:
PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Reported as:
Median · Hours (h)
Part A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)
Hours (h)Part A Cohort 2 Group 1: Olaparib, Olaparib + AbirateronePart A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone
Olaparib alone2.000 (1.00 to 2.17)—
Olaparib + abiraterone2.080 (2.00 to 4.00)2.000 (0.500 to 3.02)
SecondaryPart A PK: Abiraterone Tmax,ss

Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone tmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

Time frame:
PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Reported as:
Median · Hours
Part A PK: Abiraterone Tmax,ss
HoursPart A Cohort 2 Group 1: Olaparib, Olaparib + AbirateronePart A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone
Abiraterone alone—2.525 (1.00 to 3.00)
Olaparib + abiraterone3.000 (1.08 to 3.00)2.500 (2.00 to 3.02)
SecondaryPart A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)

Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmin,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

Time frame:
PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Reported as:
Geometric mean · mcg/mL
Part A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)
mcg/mLPart A Cohort 2 Group 1: Olaparib, Olaparib + AbirateronePart A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone
Olaparib alone1.264 ± 46.58—
Olaparib + abiraterone0.9170 ± 31.561.279 ± 65.36
SecondaryPart A PK: Abiraterone Cmin,ss

Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmin,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

Time frame:
PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Reported as:
Geometric mean · ng/mL
Part A PK: Abiraterone Cmin,ss
ng/mLPart A Cohort 2 Group 1: Olaparib, Olaparib + AbirateronePart A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone
Abiraterone alone—8.376 ± 96.52
Olaparib + abiraterone7.983 ± 163.36.358 ± 50.96
SecondaryPart A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)

Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib AUCss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

Time frame:
PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Reported as:
Geometric mean · mcg*h/mL
Part A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)
mcg*h/mLPart A Cohort 2 Group 1: Olaparib, Olaparib + AbirateronePart A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone
Olaparib alone45.27 ± 31.89—
Olaparib + abiraterone40.83 ± 11.4749.51 ± 37.30
SecondaryPart A PK: Abiraterone AUCss

Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone AUCss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone. Only patients with data available for analysis at each time point are presented.

Time frame:
PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Reported as:
Geometric mean · ng*h/mL
Part A PK: Abiraterone AUCss
ng*h/mLPart A Cohort 2 Group 1: Olaparib, Olaparib + AbirateronePart A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone
Abiraterone alone—825.5 ± 105.5
Olaparib + abiraterone718.9 ± 102.0524.6 ± 37.65
SecondaryPart B: Percentage of Patients Experiencing AEs

The safety and tolerability of olaparib when given in combination with abiraterone was assessed during Part B of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented. Severity of AEs was assessed using the NCI Common Terminology CTCAE v4.0. AEs were assigned to a Grade from 1 through 5 as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. 'c-r' = causally related. 'discont' = discontinuation. 'ola/pla' = olaparib/placebo.

Time frame:
From first dose of study treatment following randomisation in Part B up to 30 days following last dose of study treatment (up to approximately 3 years).
Reported as:
Number · Percentage of patients
Part B: Percentage of Patients Experiencing AEs
Percentage of patientsPart B: Olaparib + AbirateronePart B: Placebo + Abiraterone
Any AE c-r to ola/pla + abiraterone45.112.7
Any AE c-r to ola/pla only18.39.9
Any AE c-r to abiraterone only1.47.0
Any AE CTCAE Grade 3 or higher53.528.2
Any AE CTCAE Grade 3 or higher c-r to ola/pla23.95.6
Any AE CTCAE Grade 3 or higher c-r to abiraterone16.91.4
Any AE with outcome = death5.61.4
Any AE with outcome = death c-r to ola/pla1.40
Any AE with outcome = death c-r to abiraterone00
Any SAE35.219.7
Any SAE c-r to ola/pla9.91.4
Any SAE c-r to abiraterone5.60
Any AE causing discont of ola/pla29.69.9
Any AE causing discont of treatment c-r to ola/pla16.95.6
Any AE causing discont treatment c-r abiraterone8.51.4
SecondaryPart B: Median Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Levels

The best percentage change from baseline in PSA levels was determined to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone. The best percentage change was defined as the biggest reduction in PSA level compared with baseline or smallest increase in the absence of a decrease.

Time frame:
From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.
Reported as:
Median · Percentage change in PSA level
Part B: Median Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Levels
Percentage change in PSA levelPart B: Olaparib + AbirateronePart B: Placebo + Abiraterone
Part B: Median Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Levels-54.16 (-100.0 to 533.2)-49.85 (-100.0 to 230.1)
SecondaryPart B: Percentage of Patients With PSA Responses

The percentages of patients with single visit responses and with confirmed responses are presented to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone. A single visit response was defined as any post-dose visit PSA level reduced by 50% or more compared with baseline. A confirmed response was defined as a reduction in PSA level of 50% or more on 2 consecutive occasions at least 4 weeks apart compared with baseline. Patients may have had more than 1 single visit response or confirmed response but were counted once.

Time frame:
From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.
Reported as:
Number · Percentage of patients
Part B: Percentage of Patients With PSA Responses
Percentage of patientsPart B: Olaparib + AbirateronePart B: Placebo + Abiraterone
Single visit response50.7 (43.10 to 58.31)47.9 (40.29 to 55.49)
Confirmed response47.9 (40.29 to 55.49)42.3 (34.74 to 49.77)
SecondaryPart B: Median Best Percentage Change From Baseline in Circulating Tumour Cell (CTC) Level

The median best percentage change from baseline in CTC levels was determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone. The best percentage change was defined as the biggest CTC level reduction compared with baseline or smallest increase in the absence of a decrease.

Time frame:
From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.
Reported as:
Median · Percentage change in CTC level
Part B: Median Best Percentage Change From Baseline in Circulating Tumour Cell (CTC) Level
Percentage change in CTC levelPart B: Olaparib + AbirateronePart B: Placebo + Abiraterone
Part B: Median Best Percentage Change From Baseline in Circulating Tumour Cell (CTC) Level-1.0 (-478 to 613)-1.0 (-1279 to 414)
SecondaryPart B: Percentage of Patients With at Least One Objective Response (Objective Response Rate [ORR])

The overall radiological ORR was calculated to assess the anti-tumour activity of olaparib in combination with abiraterone, compared with placebo in combination with abiraterone. The best overall ORR was defined as the percentage of patients with at least 1 visit response of complete response (CR) or partial response (PR) in soft tissue disease assessed by RECIST 1.1 and also bone scan status of non-progressive disease or non-evaluable for their bone scans assessed by PCWG-2. CR: Disappearance of all target lesions. Reduction of pathological lymph nodes to \<10 millimetres. PR: At least a 30% decrease in the sum of diameters of target lesions from baseline. The percentage of patients with a response is presented.

Time frame:
From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.
Reported as:
Number · Percentage of patients
Part B: Percentage of Patients With at Least One Objective Response (Objective Response Rate [ORR])
Percentage of patientsPart B: Olaparib + AbirateronePart B: Placebo + Abiraterone
Part B: Percentage of Patients With at Least One Objective Response (Objective Response Rate [ORR])27.331.6
Statistical analysis
  • Part B: Olaparib + Abiraterone vs Part B: Placebo + Abiraterone · Regression, Logistic · p = 0.309 (The p value was calculated with a 1-sided significance level of 2.5%.) · Odds ratio (or): 0.813 · 95% CI 0.285 to 2.261
SecondaryMedian Time to First Subsequent Therapy (TFST) and Median Time to Second Subsequent Therapy (TSST)

The TFST and TSST were determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone. TFST was defined as the time from randomisation to the earlier of first subsequent anti-cancer therapy start date following study treatment discontinuation, or death. TSST was defined as the time from randomisation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death.

Time frame:
From randomisation until analysis cut-off date (up to approximately 3 years).
Reported as:
Median · Months
Median Time to First Subsequent Therapy (TFST) and Median Time to Second Subsequent Therapy (TSST)
MonthsPart B: Olaparib + AbirateronePart B: Placebo + Abiraterone
TFST13.5 (11.1 to 17.2)9.7 (7.3 to 12.9)
TSST19.6 (16.5 to 25.1)18.0 (16.9 to 20.6)
Statistical analysis
  • Part B: Olaparib + Abiraterone vs Part B: Placebo + Abiraterone · Log Rank · p = 0.095 (The p value was calculated with a 1-sided significance level of 2.5%.) · Hazard ratio (hr): 0.781 · 95% CI 0.540 to 1.130
  • Part B: Olaparib + Abiraterone vs Part B: Placebo + Abiraterone · Log Rank · p = 0.147 (The p value was calculated with a 1-sided significance level of 2.5%.) · Hazard ratio (hr): 0.809 · 95% CI 0.545 to 1.201
SecondaryPart B: Median Overall Survival (OS)

OS was determined to assess the efficacy of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone. OS was performed at the time of the analysis of rPFS, and the median OS, calculated using the Kaplan-Meier technique, is presented.

Time frame:
From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.
Reported as:
Median · Months
Part B: Median Overall Survival (OS)
MonthsPart B: Olaparib + AbirateronePart B: Placebo + Abiraterone
Part B: Median Overall Survival (OS)22.7 (17.4 to 29.4)20.9 (17.6 to 26.3)
Statistical analysis
  • Part B: Olaparib + Abiraterone vs Part B: Placebo + Abiraterone · Log Rank · p = 0.331 (The p value was calculated with a 1-sided significance level of 2.5%.) · Hazard ratio (hr): 0.911 · 95% CI 0.600 to 1.384
SecondaryPart B: Median Time to Second Progression or Death (PFS2)

The efficacy of olaparib when given in combination with abiraterone was assessed by PFS2, defined by local standard clinical practice and included objective radiological progression by RECIST 1.1 (soft tissue), symptomatic progression, rise in PSA level or death in the absence of overall progression.

Time frame:
From randomisation until analysis cut-off date (up to approximately 3 years).
Reported as:
Median · Months
Part B: Median Time to Second Progression or Death (PFS2)
MonthsPart B: Olaparib + AbirateronePart B: Placebo + Abiraterone
Part B: Median Time to Second Progression or Death (PFS2)23.3 (17.4 to NA)18.5 (16.1 to 23.8)
Statistical analysis
  • Part B: Olaparib + Abiraterone vs Part B: Placebo + Abiraterone · Log Rank · p = 0.140 (The p value was calculated with a 1-sided significance level of 2.5%.) · Hazard ratio (hr): 0.788 · 95% CI 0.511 to 1.215

Adverse events

Collected over Part A: From baseline (Day 1 for each cohort) up to 30 days following last dose of study treatment. Part B: From first dose of study treatment following randomisation up to 30 days following last dose of study treatment (up to approximately 3 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Cohort 1: Olaparib 200 mg + Abiraterone0/3 (0%)2/3 (66.7%)3/3 (100%)
Part A Cohort 2: Olaparib 300 mg + Abiraterone1/13 (7.7%)3/13 (23.1%)7/13 (53.8%)
Part B: Olaparib + Abiraterone43/71 (60.6%)25/71 (35.2%)63/71 (88.7%)
Part B: Placebo + Abiraterone45/71 (63.4%)14/71 (19.7%)52/71 (73.2%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventPart A Cohort 1: Olaparib 200 mg + AbirateronePart A Cohort 2: Olaparib 300 mg + AbirateronePart B: Olaparib + AbirateronePart B: Placebo + Abiraterone
PyrexiaGeneral disorders1/30/130/710/71
PneumoniaInfections and infestations1/30/134/713/71
Urinary tract infectionInfections and infestations1/30/132/712/71
Humerus fractureInjury, poisoning and procedural complications1/30/130/710/71
Eye haemorrhageEye disorders0/31/130/710/71
Intestinal obstructionGastrointestinal disorders0/31/130/710/71
CellulitisInfections and infestations0/31/130/710/71
AnaemiaBlood and lymphatic system disorders0/30/135/711/71
Acute myocardial infarctionCardiac disorders0/30/132/710/71
Myocardial infarctionCardiac disorders0/30/132/710/71
Most frequent other events
Showing 10 of 102
Most frequent other events
EventPart A Cohort 1: Olaparib 200 mg + AbirateronePart A Cohort 2: Olaparib 300 mg + AbirateronePart B: Olaparib + AbirateronePart B: Placebo + Abiraterone
Back painMusculoskeletal and connective tissue disorders3/31/1317/7114/71
DiarrhoeaGastrointestinal disorders2/33/1311/718/71
NauseaGastrointestinal disorders2/32/1327/7115/71
Rectal haemorrhageGastrointestinal disorders2/30/131/710/71
Lower respiratory tract infectionInfections and infestations2/30/130/713/71
FallInjury, poisoning and procedural complications2/31/135/711/71
Musculoskeletal chest painMusculoskeletal and connective tissue disorders2/30/131/715/71
Tympanic membrane perforationEar and labyrinth disorders1/30/130/710/71
Ocular hyperaemiaEye disorders1/31/130/710/71
Abdominal discomfortGastrointestinal disorders1/30/130/711/71

Baseline characteristics

The Safety analysis set consisted of all patients who received at least 1 dose of study treatment in Part A and all patients randomised into Part B of the study who received at least 1 dose of study treatment.

Age, Categorical
Age, Categorical(Participants)Part A Cohort 1: Olaparib 200 mg + AbirateronePart A Cohort 2: Olaparib 300 mg + AbirateronePart B: Olaparib + AbirateronePart B: Placebo + AbirateroneTotal
<=18 years00000
Between 18 and 65 years03172242
>=65 years3105449116
Sex: Female, Male
Sex: Female, Male(Participants)Part A Cohort 1: Olaparib 200 mg + AbirateronePart A Cohort 2: Olaparib 300 mg + AbirateronePart B: Olaparib + AbirateronePart B: Placebo + AbirateroneTotal
Female00000
Male3137171158
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A Cohort 1: Olaparib 200 mg + AbirateronePart A Cohort 2: Olaparib 300 mg + AbirateronePart B: Olaparib + AbirateronePart B: Placebo + AbirateroneTotal
Hispanic or Latino1011517
Not Hispanic or Latino2135863136
Unknown or Not Reported00235
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A Cohort 1: Olaparib 200 mg + AbirateronePart A Cohort 2: Olaparib 300 mg + AbirateronePart B: Olaparib + AbirateronePart B: Placebo + AbirateroneTotal
American Indian or Alaska Native00000
Asian00101
Native Hawaiian or Other Pacific Islander00000
Black or African American00112
White3136767150
More than one race00000
Unknown or Not Reported00235
08

Study locations

41 sites
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    Lake Success, New York 11041, United States
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Wilrijk, 2610, Belgium
  • Research Site
    London, Ontario N6A 4G5, Canada
  • Research Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Research Site
    Montreal, Quebec H2L 4M1, Canada
  • Research Site
    Brno, 656 53, Czechia
  • Research Site
    Brno, 656 91, Czechia
  • Research Site
    Liberec, 460 63, Czechia
  • Research Site
    Angers, 49933, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    LYON cedex 08, 69373, France
  • Research Site
    Lecce, 73100, Italy
  • Research Site
    Mirano, 30035, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Parma, 43100, Italy
  • Research Site
    Pisa, 56126, Italy
  • Research Site
    Arnhem, 6815 AD, Netherlands
  • Research Site
    Maastricht, 6202 AZ, Netherlands
  • Research Site
    Nijmegen, 6532 SZ, Netherlands
  • Research Site
    Gdańsk, 80-214, Poland
  • Research Site
    Warszawa, 02-781, Poland
  • Research Site
    Ivanovo, 153040, Russian Federation
  • Research Site
    Moscow, 115478, Russian Federation
  • Research Site
    Moscow, 125284, Russian Federation
  • Research Site
    St. Petersburg, 197022, Russian Federation
  • Research Site
    Badalona, 08916, Spain
  • Research Site
    Córdoba, 14004, Spain
  • Research Site
    Gerona, 17007, Spain
  • Research Site
    L'Hospitalet de Llobregat, 08908, Spain
  • Research Site
    Madrid, 28050, Spain
  • Research Site
    Palma de Mallorca, 7014, Spain
  • Research Site
    Valencia, 46010, Spain
  • Research Site
    Cardiff, CF14 2TL, United Kingdom
  • Research Site
    Exeter, EX2 5DW, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Plymouth, PL6 8DH, United Kingdom
  • Research Site
    Torquay, TQ2 7AA, United Kingdom
  • Research Site
    Westcliff-on-Sea, SS0 0RY, United Kingdom
09

References and documents

Publications

  • Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Flechon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4. PubMed 29880291 ↗
  • Saad F, Thiery-Vuillemin A, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Flechon A, Redfern C, Kang J, Burgents J, Gresty C, Degboe A, Clarke NW. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2022 Oct;23(10):1297-1307. doi: 10.1016/S1470-2045(22)00498-3. Epub 2022 Sep 2. Erratum In: Lancet Oncol. 2022 Oct;23(10):e446. doi: 10.1016/S1470-2045(22)00570-8. PubMed 36063830 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Sep 2017, 41 months.

Results were first posted in Oct 2018, 1 year after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 41 months is above that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2013
First posted
Oct 30, 2013
StartActual
Apr 1, 2014
Primary completionActual
Sep 22, 2017
CompletionActual
Aug 24, 2023
Results first posted
Oct 2, 2018
Last update
Nov 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01972217
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 30, 2013
Start date
Apr 1, 2014
Primary completion
Sep 22, 2017
Completion
Aug 24, 2023
Results posted
Oct 2, 2018
Last update
Nov 14, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion